EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Timing of Debridement, Antibiotics, and Implant Retention for Early Periprosthetic Joint Infection

Hannes Keemu iD, Eetu Syystö iD, Riku Klén iD, Mikko S Venäläinen iD, Matias Hemmilä iD, Jutta Järvelin, Antti P Eskelinen iD, Keijo T Mäkelä iD

Journal of Bone and Joint Surgery · 2025

DOI: 10.2106/jbjs.25.00946 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Bone and Joint Surgery, 2025. Verfasst von Hannes Keemu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics and Traumatology, Turku University Hospital, and University of Turku, Turku, Finland. Hauptthemen laut MEDLINE: Prosthesis-Related Infections, Debridement, Arthroplasty, Replacement, Hip, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Debridement, antibiotics, and implant retention (DAIR) is the method of choice in the treatment of acute periprosthetic joint infection (PJI). However, the optimal timing of DAIR is somewhat unclear. We assessed the success of DAIR performed during different time intervals after primary total hip arthroplasty (THA) and total knee arthroplasty (TKA) using data from the Finnish Arthroplasty Register (FAR).

Methods

There were 178,498 primary operations (78,888 THAs and 99,610 TKAs) from May 2014 to April 2022 recorded in the FAR. Male patients represented 53.4% of the THA group and 55.5% of the TKA group. The most common age group was ≤62 years in the THA group and ≥76 years in the TKA group. All patients were of Finnish ethnicity. A total of 1,014 DAIR procedures were performed within 6 months after the primary arthroplasty. Cases of reoperation after DAIR were followed for 1 year after the DAIR; re-revision due to PJI within 1 year was regarded as a failure of the DAIR treatment. We compared the failure rate of DAIR among 3 time intervals: 0 to 42, 43 to 84, and 85 to 180 days after the primary operation. A Cox regression model was used to assess risk factors for re-revision.

Results

In the THA group, the failure rate was 15.1% when DAIR was performed within 42 days, 10.0% when performed at 43 to 84 days, and 31.4% when performed at 85 to 180 days after the primary THA. In the TKA group, the failure rate was 8.9% when DAIR was performed within 42 days, 16.7% when performed at 43 to 84 days, and 9.8% when performed at 85 to 180 days after the primary TKA. Later DAIR was not associated with an increased re-revision risk, compared with the reference of 0 to 42 days, in the THA group (43 to 84 days: hazard ratio [HR], 1.2 [95% confidence interval (CI), 0.6 to 2.2; p = 0.63]; 85 to 180 days: HR, 1.4 [95% CI, 0.6 to 3.0; p = 0.41]). The same was true in the TKA group (43 to 84 days: HR, 1.0 [95% CI, 0.4 to 2.4; p = 0.98]; 85 to 180 days: HR, 1.9 [95% CI, 1.0 to 3.8; p = 0.065]).

Conclusions

The failure rate of DAIR may not increase as much as previously thought if performed >6 weeks after primary total joint arthroplasty. Thus, DAIR can also be worth considering as a treatment method for PJI beyond the first 6 weeks postoperatively, depending on the severity of the case. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prosthesis-Related InfectionsDebridementArthroplasty, Replacement, HipAnti-Bacterial AgentsArthroplasty, Replacement, KneeProsthesis RetentionHumansMaleAgedFemaleFinlandMiddle AgedRegistriesReoperationTime FactorsHip ProsthesisAged, 80 and overAdultTreatment OutcomeKnee Prosthesis

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Orthopaedics and Traumatology, Turku University Hospital, and University of Turku, Turku, Finland.
  • Turku PET Centre, University of Turku, and Turku University Hospital, Turku, Finland.
  • Department of Medical Physics, Turku University Hospital, and University of Turku, Turku, Finland.
  • Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Coxa Hospital for Joint Replacement and Faculty of Medicine and Health Technologies, University of Tampere, Tampere, Finland.

ORCID-Profile: Hannes Keemu, Eetu Syystö, Riku Klén, Mikko S Venäläinen, Matias Hemmilä, Antti P Eskelinen, Keijo T Mäkelä

Zitieren

APA

Keemu, H., Syystö, E., Klén, R., Venäläinen, M. S., Hemmilä, M., Järvelin, J., Eskelinen, A. P., & Mäkelä, K. T. (2025). Timing of Debridement, Antibiotics, and Implant Retention for Early Periprosthetic Joint Infection. Journal of Bone and Joint Surgery. https://doi.org/10.2106/jbjs.25.00946

Vancouver

Keemu H, Syystö E, Klén R, Venäläinen MS, Hemmilä M, Järvelin J, et al. Timing of Debridement, Antibiotics, and Implant Retention for Early Periprosthetic Joint Infection. Journal of Bone and Joint Surgery. 2025. doi:10.2106/jbjs.25.00946

BibTeX
@article{Keemu2025,
  author = {Keemu, Hannes and Syystö, Eetu and Klén, Riku and Venäläinen, Mikko S and Hemmilä, Matias and Järvelin, Jutta and Eskelinen, Antti P and Mäkelä, Keijo T},
  title = {Timing of Debridement, Antibiotics, and Implant Retention for Early Periprosthetic Joint Infection},
  journal = {Journal of Bone and Joint Surgery},
  year = {2025},
  doi = {10.2106/jbjs.25.00946}
}
Kostenlos starten →